hase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia.

Trial Profile

hase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs Perifosine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Planned end date changed from 1 Nov 2008 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top